We have a proven track record of success in technology discovery, device development, FDA approval and commercialization.
President and Chief Executive Officer
Timothy Fischer has been a pioneer in the in vitro diagnostics industry in the fields of hematology, oncology and pathology for the past 25 years. He has led the design, development and commercialization of dozens of novel diagnostic products. He holds over 40 patents and has authored numerous publications. Prior to joining HemoSonics, Fischer served as Chief Operating Officer for LipoScience, a publicly traded in-vitro diagnostics company, where he led the successful development of the Vantera® Clinical Analyzer from concept through development, regulatory approval and market adoption. Previously, he served as Vice President of Development for the Women’s Health and Cancer business unit at Becton Dickinson and as the Vice President of Product Development for TriPath Oncology. Fischer holds a Bachelor of Science degree in Biology from Indiana University.
Founder and Chief Technology Officer
William Walker, PhD, has 25 years of experience in the development of medical ultrasound technology, with expertise in instrumentation, ultrasound physics, clinical applications, intellectual property and market assessment. He has been an active founder in three ultrasound-based medical device companies. Walker applied his entrepreneurial temperament as a faculty member at the University of Virginia from 1997 to 2010. He has a proven ability to build and motivate world-class technology development teams, garner the resources to support them, and achieve dramatic breakthroughs. Walker holds both BSE and PhD degrees in Biomedical Engineering from Duke University. Walker currently splits his time between HemoSonics and Duke University, where he is Director of Engineering Entrepreneurial Ventures.
Founder and Chief Scientific Officer
Francesco Viola, PhD, has more than 10 years of experience in the area of medical ultrasound imaging, advanced signal processing and development of medical instrumentation. Viola has published his research in numerous engineering and biomedical peer-reviewed journals and he is the co-inventor in a number of patents in the field of ultrasound imaging and sensing. He is also the first recipient of The Emerging Technologies and Healthcare Innovations Congress (TETHIC) Award for achievements in scholarship and contributions to healthcare technology translation. Viola holds a Laurea in Biomedical Engineering from the Polytechnic University of Milan, Italy, and a PhD in Biomedical Engineering from the University of Virginia.
Vice President Marketing and Business Development
Megan Shaw has more than 10 years of experience growing early-stage companies. She has developed and executed on strategic growth plans in the retail, financial services and manufacturing sectors. She previously held consulting, project management and due diligence positions at the strategic consulting firms Monitor Group and Fitzgerald Analytics. Shaw also has a background in private equity where she conducted diligence on potential investments and developed growth strategies for portfolio companies. She holds a Bachelor of Arts degree in Economics from Amherst College.
Vice President Quality Systems
David Bryant has 25 years of experience in the development and manufacture of in vitro diagnostics and laboratory automation. He has successfully led product development efforts from concept through worldwide release. In addition to product development and program management, he has experience in validation, calibration, process engineering and high-speed automation. Bryant earned a Bachelor of Science degree in Industrial Engineering from North Carolina State University.
Vice President Engineering
Thomas Givens has 30 years experience leading interdisciplinary engineering teams and developing medical devices. He has developed in vitro diagnostic devices based on a variety of detection technologies for multiple clinical laboratory areas. Givens earned a Bachelor of Science in Biomedical Engineering from The University of Tennessee and a Masters of Science in Mechanical Engineering from Duke University.
Deborah Winegar PhD
Vice President Clinical Affairs
Deborah Winegar has more than 20 years of experience managing clinical and discovery research efforts at a variety of healthcare, medical device and pharmaceutical organizations. She has led multi-disciplinary project teams focused on the discovery and development of therapeutic agents, biomarkers and diagnostic products in the cardiovascular and metabolic disease areas. Prior to joining HemoSonics, Winegar served in multiple roles at GlaxoSmithKline, as Director of Research at Surgical Review Corporation and as Senior Director of Clinical Trials at LipoScience. She earned a Bachelor of Science degree in Chemistry from Notre Dame College and a PhD in Biochemistry from the University of Virginia.
- Stago Group acquires HemoSonics LLC
- Anesthesia & Analgesia Profiles Quantra’s SEER Technology in Article of the Month and Podcast
- Abstract on SEER Technology to be Presented at PGA
- HemoSonics’ Groundbreaking System for the Management of Critical Bleeding Presented in Four Articles in Anesthesia & Analgesia